Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers

Sara Rae Hamilton, Mandana Veiseh, Cornelia Tölg, Rommel Tirona, Jakob Richardson, Richard Brown, Mario Gonzalez, Michael Vanzieleghem, Patricia Anderson, Samuel Asculai, Françoise Winnik, Rashmin Savani, David Freeman, Leonard Luyt, James Koropatnick, Eva Ann Turley

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The pharmacodynamics and elimination kinetics of escalating doses (1.5-12 mg/kg) of hyaluronan (HA) infusions were studied in healthy human volunteers. Metabolic breakdown of serum HA and associated adverse events were monitored throughout the study. The HA-binding capacities of circulating CD4+ and CD8+ T lymphocytes, CD19+ B-lymphocytes and CD14+ peripheral blood monocytes (PBMC) were also quantified. Breakdown of infused HA into small fragments (<37 kDa) were not detected and adverse events related to HA infusions were infrequent and non-serious in nature. Binding of FITC-HA was greatest to CD14+ monocytes and the binding capacity of these cells for FITC-HA was significantly increased by the final HA infusion. At that time, binding to CD14+ monocytes was related to serum HA levels suggesting a close relationship between PK and PD of serum HA. Drug level analysis demonstrated a disproportional increase in the area under the serum concentration vs. time curve with increasing HA dose. The observed non-linear HA kinetics appears to result from a saturable elimination process as revealed by pharmacokinetic modeling. These results have implications for the use of injected HA for drug delivery or in imaging applications.

Original languageEnglish (US)
Pages (from-to)43-55
Number of pages13
JournalOpen Drug Metabolism Journal
Volume3
DOIs
StatePublished - 2009

Fingerprint

Hyaluronic Acid
Healthy Volunteers
Pharmacokinetics
Monocytes
Fluorescein-5-isothiocyanate
Serum
Pharmaceutical Preparations
B-Lymphocytes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hamilton, S. R., Veiseh, M., Tölg, C., Tirona, R., Richardson, J., Brown, R., ... Turley, E. A. (2009). Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers. Open Drug Metabolism Journal, 3, 43-55. https://doi.org/10.2174/1874073100903010043

Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers. / Hamilton, Sara Rae; Veiseh, Mandana; Tölg, Cornelia; Tirona, Rommel; Richardson, Jakob; Brown, Richard; Gonzalez, Mario; Vanzieleghem, Michael; Anderson, Patricia; Asculai, Samuel; Winnik, Françoise; Savani, Rashmin; Freeman, David; Luyt, Leonard; Koropatnick, James; Turley, Eva Ann.

In: Open Drug Metabolism Journal, Vol. 3, 2009, p. 43-55.

Research output: Contribution to journalArticle

Hamilton, SR, Veiseh, M, Tölg, C, Tirona, R, Richardson, J, Brown, R, Gonzalez, M, Vanzieleghem, M, Anderson, P, Asculai, S, Winnik, F, Savani, R, Freeman, D, Luyt, L, Koropatnick, J & Turley, EA 2009, 'Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers', Open Drug Metabolism Journal, vol. 3, pp. 43-55. https://doi.org/10.2174/1874073100903010043
Hamilton, Sara Rae ; Veiseh, Mandana ; Tölg, Cornelia ; Tirona, Rommel ; Richardson, Jakob ; Brown, Richard ; Gonzalez, Mario ; Vanzieleghem, Michael ; Anderson, Patricia ; Asculai, Samuel ; Winnik, Françoise ; Savani, Rashmin ; Freeman, David ; Luyt, Leonard ; Koropatnick, James ; Turley, Eva Ann. / Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers. In: Open Drug Metabolism Journal. 2009 ; Vol. 3. pp. 43-55.
@article{01660a3c6265453999b3f806cb44a517,
title = "Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers",
abstract = "The pharmacodynamics and elimination kinetics of escalating doses (1.5-12 mg/kg) of hyaluronan (HA) infusions were studied in healthy human volunteers. Metabolic breakdown of serum HA and associated adverse events were monitored throughout the study. The HA-binding capacities of circulating CD4+ and CD8+ T lymphocytes, CD19+ B-lymphocytes and CD14+ peripheral blood monocytes (PBMC) were also quantified. Breakdown of infused HA into small fragments (<37 kDa) were not detected and adverse events related to HA infusions were infrequent and non-serious in nature. Binding of FITC-HA was greatest to CD14+ monocytes and the binding capacity of these cells for FITC-HA was significantly increased by the final HA infusion. At that time, binding to CD14+ monocytes was related to serum HA levels suggesting a close relationship between PK and PD of serum HA. Drug level analysis demonstrated a disproportional increase in the area under the serum concentration vs. time curve with increasing HA dose. The observed non-linear HA kinetics appears to result from a saturable elimination process as revealed by pharmacokinetic modeling. These results have implications for the use of injected HA for drug delivery or in imaging applications.",
author = "Hamilton, {Sara Rae} and Mandana Veiseh and Cornelia T{\"o}lg and Rommel Tirona and Jakob Richardson and Richard Brown and Mario Gonzalez and Michael Vanzieleghem and Patricia Anderson and Samuel Asculai and Fran{\cc}oise Winnik and Rashmin Savani and David Freeman and Leonard Luyt and James Koropatnick and Turley, {Eva Ann}",
year = "2009",
doi = "10.2174/1874073100903010043",
language = "English (US)",
volume = "3",
pages = "43--55",
journal = "Open Drug Metabolism Journal",
issn = "1874-0731",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers

AU - Hamilton, Sara Rae

AU - Veiseh, Mandana

AU - Tölg, Cornelia

AU - Tirona, Rommel

AU - Richardson, Jakob

AU - Brown, Richard

AU - Gonzalez, Mario

AU - Vanzieleghem, Michael

AU - Anderson, Patricia

AU - Asculai, Samuel

AU - Winnik, Françoise

AU - Savani, Rashmin

AU - Freeman, David

AU - Luyt, Leonard

AU - Koropatnick, James

AU - Turley, Eva Ann

PY - 2009

Y1 - 2009

N2 - The pharmacodynamics and elimination kinetics of escalating doses (1.5-12 mg/kg) of hyaluronan (HA) infusions were studied in healthy human volunteers. Metabolic breakdown of serum HA and associated adverse events were monitored throughout the study. The HA-binding capacities of circulating CD4+ and CD8+ T lymphocytes, CD19+ B-lymphocytes and CD14+ peripheral blood monocytes (PBMC) were also quantified. Breakdown of infused HA into small fragments (<37 kDa) were not detected and adverse events related to HA infusions were infrequent and non-serious in nature. Binding of FITC-HA was greatest to CD14+ monocytes and the binding capacity of these cells for FITC-HA was significantly increased by the final HA infusion. At that time, binding to CD14+ monocytes was related to serum HA levels suggesting a close relationship between PK and PD of serum HA. Drug level analysis demonstrated a disproportional increase in the area under the serum concentration vs. time curve with increasing HA dose. The observed non-linear HA kinetics appears to result from a saturable elimination process as revealed by pharmacokinetic modeling. These results have implications for the use of injected HA for drug delivery or in imaging applications.

AB - The pharmacodynamics and elimination kinetics of escalating doses (1.5-12 mg/kg) of hyaluronan (HA) infusions were studied in healthy human volunteers. Metabolic breakdown of serum HA and associated adverse events were monitored throughout the study. The HA-binding capacities of circulating CD4+ and CD8+ T lymphocytes, CD19+ B-lymphocytes and CD14+ peripheral blood monocytes (PBMC) were also quantified. Breakdown of infused HA into small fragments (<37 kDa) were not detected and adverse events related to HA infusions were infrequent and non-serious in nature. Binding of FITC-HA was greatest to CD14+ monocytes and the binding capacity of these cells for FITC-HA was significantly increased by the final HA infusion. At that time, binding to CD14+ monocytes was related to serum HA levels suggesting a close relationship between PK and PD of serum HA. Drug level analysis demonstrated a disproportional increase in the area under the serum concentration vs. time curve with increasing HA dose. The observed non-linear HA kinetics appears to result from a saturable elimination process as revealed by pharmacokinetic modeling. These results have implications for the use of injected HA for drug delivery or in imaging applications.

UR - http://www.scopus.com/inward/record.url?scp=77953379629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953379629&partnerID=8YFLogxK

U2 - 10.2174/1874073100903010043

DO - 10.2174/1874073100903010043

M3 - Article

AN - SCOPUS:77953379629

VL - 3

SP - 43

EP - 55

JO - Open Drug Metabolism Journal

JF - Open Drug Metabolism Journal

SN - 1874-0731

ER -